Business Context and Reporting Period
This Form 8-K was filed by Anthem, Inc. (now Elevance Health, Inc.) on June 7, 2016. The report serves as a Regulation FD disclosure regarding upcoming communications with securities analysts and investors scheduled between June 7, 2016, and June 30, 2016.
Key Financial Metrics and Guidance
The filing does not report historical revenue, profit, cash flow, or debt figures for a specific period. Instead, it provides management's reaffirmed full-year 2016 earnings guidance:
- Net Income Guidance: Greater than $9.65 per share.
- Unfavorable Items: Includes greater than $1.15 per share of net unfavorable items.
- Adjusted Net Income: Excluding unfavorable items, the company expects adjusted net income to be greater than $10.80 per share.
- Adjustment Scope: Guidance excludes any adjustment items beyond those reported in the first quarter 2016 earnings release.
Material Changes and Outlook
Management intends to reaffirm the previously stated 2016 guidance during the specified period. The filing highlights significant strategic and operational factors influencing the outlook:
- Pending Acquisition: The company is pursuing the acquisition of Cigna Corporation. Risks include the ability to achieve synergies, integration challenges, and the possibility that the deal may not close due to regulatory approvals or other conditions.
- Regulatory Environment: Ongoing impacts from the Patient Protection and Affordable Care Act, including uncertainties in Individual and Small Group markets and premium rate adequacy.
- Cybersecurity: Continued risks related to the February 2015 cyber-attack, including investigations, claims, and litigation.
Risks and Contingencies
The document contains extensive forward-looking statements subject to numerous risks, including:
- Government regulation and taxation of health benefits.
- Trends in health care costs and utilization rates.
- Ability to secure sufficient premium rates and regulatory approval.
- Challenges in federal and state health insurance exchanges.
- Financial strength rating downgrades.
- Litigation, government investigations, and medical malpractice claims.
- Compliance with the Express Scripts, Inc. pharmacy benefit management agreement.
- Information system modernization and data security.
- Impairment of intangible assets and goodwill.
Investor Verification Checklist
- Verify the status of the pending Cigna Corporation acquisition and any regulatory hurdles.
- Confirm the specific nature and magnitude of the $1.15 per share in net unfavorable items referenced in the guidance.
- Review the latest updates regarding the February 2015 cyber-attack and associated legal or financial liabilities.
- Monitor regulatory developments affecting premium rates in Individual and Small Group markets.
- Assess the company's ability to maintain financial strength ratings amidst the acquisition and market conditions.